Identifying Effective Durations of Antibiotic Therapy for the Treatment of Carbapenem-resistant Enterobacterales Bloodstream Infections: A Multicenter Observational Study.

Autor:	Soto CL; Department of Pharmacy, Johns Hopkins Hospital, Baltimore, Maryland, USA., Hsu AJ; Department of Pharmacy, Johns Hopkins Hospital, Baltimore, Maryland, USA., Lee JH; Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland, USA., Dzintars K; Department of Pharmacy, Johns Hopkins Hospital, Baltimore, Maryland, USA., Choudhury R; Department of Medicine, Montefiore Medical Center, Bronx, New York, USA., Jenkins TC; Department of Medicine, Denver Health, Denver, Colorado, USA., McCreary EK; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Quartuccio KS; Department of Pharmacy, University of Rochester Medical Center, Rochester, New York, USA., Stohs EJ; Department of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA., Zimmerman M; Department of Pharmacy, Johns Hopkins Hospital, Baltimore, Maryland, USA., Tamma PD; Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland, USA.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Jan 25; Vol. 78 (1), pp. 27-30.
DOI:	10.1093/cid/ciad476
Abstrakt:	In a propensity-score-weighted cohort of 183 adults with carbapenem-resistant Enterobacterales bacteremia at 24 US hospitals, patients receiving short courses of active therapy (7-10 days, median 9 days) experienced similar odds of recurrent bacteremia or death within 30 days as those receiving prolonged courses of active therapy (14-21 days, median 14 days). Competing Interests: Potential conflicts of interest. E. K. M. reports consulting fees for Advisory Boards from AbbVie, Merck, Shionogi, Cidara, Ferring, Summit, La Jolla, Venatorx, Entasis, LabSimply, and Basilea; participation on DSMB for Wockhardt and on DMBD for A Phase I, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous Ertapenem in Combination with Zidebactam (WCK 6777) in Healthy Adult Subjects; speaking honorarium for UTI symposium at ECCMID 2023 from GlaxoSmithKlein (GSK) and speaking honorarium for COVID-19 symposium at IDWeek 2022; travel support to attend ECCMID 2023 from GSK. E. S. has received grant funding from Merck & Co and bioMérieux, Inc. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu